Drug intelligence / Profile preview

SJ04

Development stage: Phase 1
Lead developer: Suzhou Shengji Pharmaceutical
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

SJ04 is a biosimilar to Ovidrel, which is a recombinant human chorionic gonadotropin (hCG) injection used for reproductive medicine indications. SJ04 is intended to have highly similar pharmacokinetics and efficacy to Ovidrel. It is administered as a single subcutaneous injection and has been studied for bioequivalence in healthy female subjects[2].

Other names: recombinant human chorionic gonadotropinr-hCG

Targets

TSHR (Thyroid-stimulating hormone receptor)

Beyond the preview

Go deeper on SJ04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SJ04.

Explore the full profile